Health

Shorter Six-Month Oral Regimens For Drug-Resistant TB Prove Cost-Effective: ICMR Study

Shorter, six-month and all-oral treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are cost-effective and deliver improved health outcomes compared to longer therapies, an Indian Council of Medical Research (ICMR) study said on Thursday.

According to a Ministry of Health and Family Welfare statement, the study found, “With the shorter regimen, for each additional Quality Adjusted Life Year (QALY) gained, the health system spends Rs 379 less per patient compared to the standard regimen, indicating better health outcomes at lower costs.”

The research compared bedaquiline-based regimens, BPaL (bedaquiline, pretomanid, and linezolid), with the existing bedaquiline-containing shorter (9–11 months) and longer (18–20 months) treatment regimens implemented under the National TB Elimination Programme (NTEP).

It also evaluated BPaLM (with moxifloxacin) against the current standard regimen and found it to be highly cost-effective, costing only Rs 37 more per patient per additional QALY gained compared with the standard regimen.

Both BPaL and BPaLM regimens were associated with lower or comparable overall healthcare expenditure, including the costs of medicines, hospital visits and follow-up care.

MDR/RR-TB remains difficult to treat due to prolonged treatment durations, adverse effects and higher financial burden.

The findings indicate that shorter all-oral regimens can enhance adherence, reduce patient morbidity and enable a quicker return to normal life, while easing pressure on the healthcare system.

“The findings provide important economic evidence to support the use of shorter, all-oral regimens for MDR or RR-TB management in India. By reducing treatment duration from 9–18 months or longer to six months, these regimens align with national priorities to optimise resource utilisation and accelerate progress towards TB elimination,” the statement said.

Meanwhile, Delhi’s Intermediate Reference Laboratory, Tuberculosis Centre, has received certification from the Central Tuberculosis Division (CTD) to conduct Drug Susceptibility Testing (DST) for bedaquiline (BDQ) and Pretomanid (Pa), used globally for drug-resistant TB treatment.

Md Shadan Ayaz

Recent Posts

PM Modi Uses GTA VI Reference To Highlight India’s Development Journey

PM Modi shared a GTA VI-inspired post showcasing India's progress in economy, energy, defence, digital…

3 hours ago

Sensex, Nifty Trade Lower As IT & Metal Stocks Face Selling Pressure

Sensex fell over 300 points while Nifty slipped in early trade on Thursday as investors…

4 hours ago

PM Modi, Amit Shah Pay Tribute To Rani Lakshmibai On Birth Anniversary

Prime Minister Narendra Modi and Union Home Minister Amit Shah paid tribute to Rani Lakshmibai…

5 hours ago

Delhi’s Air Quality Deteriorates To Poor Category, AQI Reaches 289

Delhi's air quality deteriorated on Thursday, with the Air Quality Index (AQI) reaching 289, placing…

5 hours ago

PM Modi Pays Tribute To Former Prime Minister Indira Gandhi On Her Birth Anniversary

Prime Minister Narendra Modi paid tribute to former Prime Minister Indira Gandhi on her birth…

6 hours ago

CM Yogi To Lay Foundation Stone Of UP’s First Forestry University In Gorakhpur Today

Chief Minister Yogi will lay the foundation stone of Uttar Pradesh's first Forestry and Horticulture…

7 hours ago